Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
November 07, 2022 18:55 ET
|
Intercept Pharmaceuticals, Inc.
First-in-human data shared at The Liver Meeting® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH),...
Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022
November 07, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
OCA 25 mg demonstrated double the response rate of placebo in reduction of liver fibrosis without worsening of NASH; consistent antifibrotic effect shown across multiple analyses OCA 25 mg showed...
Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
November 06, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6 MORRISTOWN, N.J., Nov. 06, 2022 (GLOBE...
Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022 07:00 ET
|
Intercept Pharmaceuticals, Inc.
U.S. Ocaliva® net sales of $77.6 million; 16.4% growth over the prior year quarter Company increases 2022 Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million and narrows...
Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
October 31, 2022 16:05 ET
|
Intercept Pharmaceuticals, Inc.
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid (OCA) in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis...
Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
October 25, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
October 12, 2022 08:00 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
September 30, 2022 07:55 ET
|
Intercept Pharmaceuticals, Inc.
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
September 21, 2022 07:30 ET
|
Intercept Pharmaceuticals, Inc.
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program,...
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
September 20, 2022 12:45 ET
|
Intercept Pharmaceuticals, Inc.
Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy Analysis compares findings from the Phase 3 POISE trial and open-label extension to...